In a report released today, Andres Y. Maldonado from H.C. Wainwright reiterated a Buy rating on Zentalis Pharmaceuticals, with a price target of $10.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Andres Y. Maldonado’s rating is based on Zentalis Pharmaceuticals’ strategic advancements in their Cyclin E1+ platinum-resistant ovarian cancer (PROC) program. The company has initiated DENALI Part 2, a pivotal Phase 2 trial aimed at supporting accelerated approval, with topline data anticipated by the end of 2026. This trial is designed to provide a non-chemotherapy treatment option for a biomarker-defined population that currently lacks approved targeted therapies, positioning azenosertib as a potential best-in-class solution.
Furthermore, Zentalis has demonstrated consistent efficacy across multiple studies, reinforcing Cyclin E1 as a reliable biomarker for predicting azenosertib response. With a cash runway extending into late 2027 and ongoing alignment with the FDA, the company is on a focused regulatory path. These factors, combined with the promising clinical data and strategic execution, underpin Maldonado’s Buy rating and the $10 price target for Zentalis Pharmaceuticals.
In another report released yesterday, TD Cowen also maintained a Buy rating on the stock with a $0.00 price target.